Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Facet Biotech Clear all
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

NCT00006045
View directory record Official record
Conditions
Leukemia
Interventions
lintuzumab, cytarabine, etoposide, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
40
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 1Phase 2 Interventional

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, Cyclosporine, cyclosporine and Daclizumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Prevention of Diabetes Progression Trial (PDPT)

NCT00198146
View directory record Official record
Conditions
Newly Diagnosed With Type 1 Diabetes
Interventions
Zenapax
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Phase 2Phase 3 Interventional

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

NCT00073047
View directory record Official record
Conditions
Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
30
States / cities
Huntsville, Alabama • Anaheim, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 1Phase 2 Interventional

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

NCT00267306
View directory record Official record
Conditions
Severe Ulcerative Colitis
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
16 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Phase 2Phase 3 Interventional

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00279422
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Not listed Phase 2 Interventional

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

NCT00032279
View directory record Official record
Conditions
Graft-vs-Host Disease
Interventions
Visilizumab
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
0 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
17
States / cities
Duarte, California • Stanford, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Phase 2 Interventional

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms
Interventions
Volociximab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

NCT00267722
View directory record Official record
Conditions
Crohn's Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288
View directory record Official record
Conditions
Asthma
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Long Beach, California • Mission Viejo, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 1Phase 2 Interventional

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, NB-UVB
Drug · Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

NCT00001061
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Sevirumab, Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Jose, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

NCT00099970
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
M200 (volociximab) in Combination with Dacarbazine (DTIC)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2Phase 3 Interventional

Research Study in Patients With Severe Ulcerative Colitis

NCT00032305
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

NCT00024544
View directory record Official record
Conditions
Asthma
Interventions
anti-IL-4 monoclonal antibody (pascolizumab)
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Los Angeles, California • Mission Viejo, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Withdrawn Phase 1 Interventional

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

NCT00487799
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Ularitide
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 1 Interventional

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

NCT00425347
View directory record Official record
Conditions
Multiple Myeloma
Interventions
HuLuc63
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

NCT00281294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Fontolizumab
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 10, 2026, 5:48 PM EST
Withdrawn Phase 2 Interventional

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

NCT00528827
View directory record Official record
Conditions
Hypertension
Interventions
Cardene® I.V.
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 1Phase 2 Interventional

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

NCT00032292
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Duarte, California • Stanford, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

NCT00267709
View directory record Official record
Conditions
Crohn's Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

NCT00072943
View directory record Official record
Conditions
Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
Interventions
anti-Interferon-gamma monoclonal antibody
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
15
States / cities
Anaheim, California • Orange, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Nov 10, 2026, 5:48 PM EST